The effectiveness of bevacizumab (Avastin) and related trials
Автор: Ovacome - the ovarian cancer charity
Загружено: 2022-06-24
Просмотров: 6513
Описание:
In this webinar the Ovacome team are joined by Professor Gordon Jayson BM, BA, Bch, FRCP, PhD, Professor of Medical Oncology at the Christie and University of Manchester.
Professor Jayson discusses the use of anti-angiogenic (anti-blood vessel) agents such as bevacizumab (Avastin) in treating ovarian cancer. He looks at the effectiveness of these drugs in the first line setting, as well as in the treatment of both platinum-sensitive and platinum-resistant recurrent disease.
Professor Jayson also gives about the new VALTIVE1 study, which is trialling a blood test that will tell doctors and patients early on whether bevacizumab (Avastin) is working. This can then inform further decisions about the right treatment for each individual.
For ovarian cancer information and support, visit https://www.ovacome.org.uk/
If you have any questions about anything discussed in this webinar, call Ovacome on 0800 008 7054 or email [email protected] .
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
